Feature

Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis

Publish date: June 1, 2023

 

FROM ARTHRITIS & RHEUMATOLOGY

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Upadacitinib earns FDA approval for ankylosing spondylitis 
MDedge Rheumatology
Methotrexate’s impact on COVID-19 vaccination: New insights made
MDedge Rheumatology
‘I shall harm’
MDedge Rheumatology
VTE risk not elevated in AD patients on JAK inhibitors: Study
MDedge Rheumatology
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Rheumatology
FDA approves upadacitinib (Rinvoq) for sixth indication
MDedge Rheumatology
JAK inhibitor safety warnings drawn from rheumatologic data may be misleading in dermatology
MDedge Rheumatology
New data forecast more oral PDE4 inhibitors for psoriasis
MDedge Rheumatology
JAK inhibitor ivarmacitinib shows efficacy for atopic dermatitis in a pivotal trial
MDedge Rheumatology
JAK-inhibitor safety in adolescents with AD: Long-term analyses reported
MDedge Rheumatology